Navigation
banner

Kei Kishimoto

Chief Scientific Officer

Selecta Biosciences

 
Kei Kishimoto

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines b ased on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provid ed the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto receive d his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Follow Kei Kishimoto' at upcoming/ongoing conferences at gtcbio:

Immunogenicity & Immunotoxicity 2018